Porton Down, UK, 5 June 2008: GW Pharmaceuticals plc (AIM: GWP) will be announcing its interim financial results for the six months ended 31 March 2008 on Thursday 19 June.

Enquiries:

Notes to Editors

About GW Pharmaceuticals

GW was founded in 1998 and listed on the AiM, a market of the London Stock Exchange in June 2001. Operating under license from the UK Home Office, the company is developing cannabis-derived pharmaceutical products for patients with multiple sclerosis, neuropathic pain, cancer pain, spinal cord injury, rheumatoid arthritis, and other severe medical conditions.

GW has assembled a team of over 100 scientists with extensive experience in developing both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW is dedicated to developing treatment options that alleviate pain symptoms in patients who suffer from serious ailments.

For further information, please visit the Company’s website: www.gwpharm.com